Back to top

Image: Bigstock

J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition

Read MoreHide Full Article

Key Takeaways

  • J&J will acquire Ollin Biosciences for $2.2B, adding phase III candidate OLN324 to its ophthalmology pipeline.
  • OLN324 targets VEGF and Ang2 to potentially improve disease control and extend treatment intervals.
  • Blackstone will provide $750M for Phase III development in exchange for milestones and single-digit royalties.

Johnson & Johnson (JNJ - Free Report) announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotech, Ollin Biosciences, for $2.2 billion. The deal also includes potential regulatory and commercial milestone payments of up to approximately $1.12 billion.

The impending acquisition will add Ollin’s OLN324, an investigational bispecific antibody currently in phase III development, to J&J's ophthalmology pipeline. The drug is being developed for retinal vascular diseases, including wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

The proposed acquisition is expected to close before the end of 2026, subject to customary closing conditions.

OLN324 is designed to target two key pathways involved in retinal diseases: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). Per JNJ, OLN324 could potentially deliver stronger and more sustained disease control, reduce retinal fluid more effectively and allow longer intervals between treatments.

JNJ Price Performance

Year to date, shares of J&J have rallied 38.7% compared with the industry’s rise of 29.1%.

Zacks Investment Research
Image Source: Zacks Investment Research

J&J Partners With Blackstone to Fund OLN324 Development

Separately, J&J will enter into a development funding agreement with Blackstone Life Sciences to support the phase III development of OLN324, contingent upon the acquisition closing.

Per the agreement, Blackstone will pay J&J a total of $750 million over multiple years to fully fund the phase III development of OLN324. In return, Blackstone will be eligible to receive certain regulatory and sales-based milestone payments, along with single-digit royalties.

The acquisition is expected to strengthen J&J's presence in ophthalmology and support its ambition to preserve, restore and enhance vision. The addition of OLN324 also underscores the company's efforts to pursue acquisitions and deals to boost its portfolio.

JNJ Seeks Expansion With M&A Push

J&J has been on an acquisition spree in recent times. In 2025, the company invested more than $32 billion in R&D and M&A, including the acquisition of Intra-Cellular Therapies, which added the antidepressant drug Caplyta to JNJ’s neuroscience portfolio.

Caplyta is approved for the treatment of schizophrenia, depression in both bipolar 1 and 2, and major depressive disorder.

Last year, J&J acquired Halda Therapeutics, which added a promising clinical-stage treatment for prostate cancer with potential across multiple tumor types.

The acquisition added Halda’s proprietary RIPTAC platform, a technology being used to develop oral, targeted therapies for multiple types of solid tumors.

In July 2026, JNJ acquired California-based biotech, Firefly Bio, for $1 billion in cash, expanding its oncology pipeline.

J&J has also pursued various acquisitions to strengthen its presence in cardiovascular diseases and rare autoantibody-driven disorders.

JNJ's Zacks Rank & Stocks to Consider

J&J currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the drug/biotech sector are Vericel (VCEL - Free Report) and Collegium Pharmaceutical (COLL - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Vericel’s 2026 earnings per share have risen from 54 cents to 78 cents, while estimates for 2027 have increased from 84 cents to 98 cents during the same time. VCEL shares have surged 59.6% year to date.

Vericel’s earnings beat estimates in three of the trailing four quarters, while meeting the same on the remaining occasion, with the average surprise being 367.50%.

Over the past 60 days, estimates for Collegium Pharmaceutical’s 2026 earnings per share have risen from $7.13 to $7.39, while estimates for 2027 have increased from $5.34 to $6.84 during the same time. COLL shares have plunged 45.1% year to date.

Collegium Pharmaceutical’s earnings beat estimates in three of the trailing four quarters, while missing estimates on the remaining occasion, with the average surprise being 10.53%.

Published in